ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.54
-0.84 (-13.17%)
Aug 20, 2026, 3:40 PM EDT - Market open
ARS Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 116.93 | 84.28 | 89.15 | 0.03 | 1.32 | 5.51 | |
Revenue Growth | 4.08% | -5.46% | 297063.33% | -97.72% | -76.10% | -69.13% |
Cost of Revenue | 48.71 | 33.6 | 20.56 | 20.27 | 17.12 | 20.27 |
Gross Profit | 68.22 | 50.67 | 68.59 | -20.24 | -15.8 | -14.77 |
Selling, General & Admin | 284.49 | 230.12 | 71.68 | 47.28 | 18.66 | 4.69 |
Operating Expenses | 284.49 | 230.12 | 71.68 | 47.28 | 18.66 | 4.69 |
Operating Income | -216.27 | -179.45 | -3.08 | -67.52 | -34.46 | -19.45 |
Interest Expense | -7.52 | -2.6 | - | - | - | -0.8 |
Interest & Investment Income | 8.27 | 10.67 | 11.37 | - | - | - |
Other Non Operating Income (Expenses) | - | - | - | 6.01 | 1.12 | 0.01 |
EBT Excluding Unusual Items | -215.51 | -171.38 | 8.29 | -61.51 | -33.34 | -20.24 |
Gain (Loss) on Sale of Investments | - | - | - | 6.85 | -0.29 | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.3 | - | - |
Pretax Income | -215.51 | -171.38 | 8.29 | -54.37 | -34.68 | -20.24 |
Income Tax Expense | -0.08 | -0.08 | 0.29 | - | - | - |
Net Income | -215.43 | -171.3 | 8 | -54.37 | -34.68 | -20.24 |
Net Income to Common | -215.43 | -171.3 | 8 | -54.37 | -34.68 | -20.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 99 | 99 | 97 | 95 | 40 | 29 |
Shares Outstanding (Diluted) | 99 | 99 | 102 | 95 | 40 | 29 |
Shares Change | 1.43% | -3.74% | 7.54% | 138.30% | 38.39% | 42.81% |
EPS (Basic) | -2.17 | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
EPS (Diluted) | -2.18 | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -196.6 | -171.21 | 12.99 | -59.44 | -40.28 | -17.62 |
Free Cash Flow Per Share | -1.98 | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 |
Gross Margin | 58.35% | 60.13% | 76.94% | - | - | -268.20% |
Operating Margin | -184.96% | -212.92% | -3.46% | -225066.67% | -2618.54% | -353.32% |
Profit Margin | -184.25% | -203.25% | 8.97% | -181216.67% | -2635.41% | -367.65% |
Free Cash Flow Margin | -168.14% | -203.14% | 14.57% | -198136.67% | -3060.56% | -319.94% |
EBITDA | -214.65 | -178.08 | -3 | -67.45 | -34.43 | -19.24 |
EBITDA Margin | -183.57% | -211.30% | -3.37% | - | - | - |
D&A For EBITDA | 1.62 | 1.37 | 0.08 | 0.07 | 0.03 | 0.21 |
EBIT | -216.27 | -179.45 | -3.08 | -67.52 | -34.46 | -19.45 |
EBIT Margin | -184.96% | -212.92% | -3.46% | - | - | - |
Effective Tax Rate | - | - | 3.48% | - | - | - |
Revenue as Reported | 116.93 | 84.28 | 89.15 | 0.03 | - | - |